2010;78(2):166 -74. 39. Yin L, Kufe D. MUC1 -C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS -Mediated Mechanism. Genes Can cer. 2011;2(1):56 -64. 40. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45 -60. 41. Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, et al. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007;67(24):11576 -84. 42. Gendler SJ, Lancaster CA, Taylor -Papadimitriou J, Duhig T, Peat N, Burchell J, et al. Molecular cloning and expression of human tumor -associated polymorphic epithelial mucin. J Biol Chem. 1990;265(25):15286 -93. 43. Kufe D, Inghirami G, Abe M, Hayes D, Justi -Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984;3(3):223 -32. 44. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA -MUC -1-TRICOM poxviral -based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14(10):3060 -9. 45. Limacher JM, Quoix E. TG4010: A therapeutic vaccine against MUC1 expressing tumors. Oncoimmunology. 2012;1(5):791 -2. Abbreviated Title: Ad5 -based combination vaccines Version Date: 05.16.2018 71 46. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC -1/CEA/TRICOM poxviral -based vaccine in pat ients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011;17(22):7164 -73. 47. Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009;8(13):1197 -203. 48. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. A hu man cytotoxic T -lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC - 1. Clin Cancer Res. 2004;10(6):2139 -49. 49. Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, et al. Identification and characterization of agonist epitopes of the MUC1 -C oncoprotein. Cancer Immunol Immunother. 2014;63(2):161 -74. 50. Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine. 1995;13(13):1143 - 51. 51. Tatsis N, Ertl HC. Adenoviruses as vaccine vect ors. Mol Ther. 2004;10(4):616 -29. 52. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther. 2007;7(3):189 -204. 53. Seregin SS, Amalfitano A. Overcoming pre -existing adenovirus immunity by ge netic engineering of adenovirus -based vectors. Expert Opin Biol Ther. 2009;9(12):1521 -31. 54. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno -associated virus in humans. Gene Ther. 1999;6(9):1574 -83. 55. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011;29(32):5203 -9. 56. Amalfitano A, Hauser MA, Hu H, Serra D, B egy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol. 1998;72(2):926 -33. 57.